Donate

The XLH Network needs your support to continue to achieve our goal to discover better treatment and ultimately a cure for this rare and neglected heritable bone disease affecting 1 in 20,000 babies and adults worldwide. To date there is no cure for XLH and the current treatment is not always successful, and if not carefully monitored it can be damaging to organs. Your contribution helps our organization continue the support and fund ongoing research and bring awareness to pediatricians so our babies can be diagnosed at an early stage improving the future for every child and adult affected with XLH. We cannot exist without your donations every donation regardless of the amount can make the difference in achieving our Mission. It is the spirit of giving that really counts. The XLH Network is currently funded entirely by donations from those people whose hearts we've touched, and we are very grateful to those individuals.

There are many ways to help us:

Checks (USA banks only) may be mailed to: 

The XLH Network, Inc.
911 Central Ave., #161
Albany, NY 12206
USA

             ~ OR ~

 You can contribute worldwide via PayPal or Credit Card:  

           Donate


Other ways to help: 
 

  • Employer Matching Gift
    Many employers have programs to match donations made by their employees.  Check with your employer to see how to add The XLH Network, Inc. to their employer matching gift program.
  • Planned Giving
    Ask your financial and legal advisors about including The XLH Network, Inc. as a beneficiary in your will or whether there may be ways to help us that would also benefit you financially while you're still alive.  
  • Shop and search online to support The XLH Network, Inc. at:

                  or              Right Click: Save Picture As

  • Donate a vehicle to support The XLH Network, Inc. at:           

    Home 

  • Fundraising Ideas

The XLH Network, Inc. is a not-for-profit corporation and is recognized in the USA as a tax-exempt 501(c)(3) publicly supported charitable organization.   

The XLH Network needs your support to continue to achieve our goal to discover better treatment and ultimately a cure for this rare and neglected heritable bone disease affecting 1 in 20,000 children and adults worldwide. To date there is no cure for XLH, and the current treatment is not always successful and often includes damaging side effects.

The XLH Network contributes to research efforts geared toward finding a cure for XLH in an attempt to improve the future for every child and adult affected with this disease. Your donations help our organization continue to raise awareness among medical and patient communities in invaluable ways.

The XLH Network is currently funded entirely by donations from those people whose families and friends are afflicted with XLH. Please consider making a donation to help ensure better lives for those living with XLH.

© 2011, The XLH Network Inc.
The authors of this web site are not medical professionals, and this information does not substitute for medical care. Information on these pages is based on biomedical research, published in peer-reviewed journals, and international research conferences. Additionally, in some cases anecdotal information is provided by subscribers of the F-HYPDRR group, a mailing list for The XLH Network Inc. A listing of XLH research is available. Please read our full disclaimer 

Top of Page

Last modified Feb 23, 2012

NewsThe XLH News Blog

    • XLH Network Survey
    • The XLH Network is currently in a year-long process of working to grow our organization and better meet the needs of the XLH community. As part of our initiatives, we have designed a survey in hopes of getting feedback from our members. Your feedback…
    • 2013 Rare Disease Day Symposium
    • In February the 2013 Rare Disease Day Symposium was held in California at the Sanford-Burnham Medical Research Institute.    This year's topic was "Calcification Disorders - from Hardened Arteries to Soft Bones".     Amo…
    • New National Institutes of Health Research Study
    • NIH Research Study: Open-label Dose-titration Study of the Tolerability and Efficacy of Cinacalcet to Treat Fibroblast Growth Factor 23 (FGF23)-mediated HypophosphatemiaPrincipal Investigator: Dr. Rachel Gafni, MDSponsoring Institute: Craniofacial and Ske…
    • Scientific Advisory Board member wins award at ASBMR
    • Michael Econs, XLH Network Scientific Advisory Board Member (SAB), was awarded the Frederic C. Bartter Award for outstanding clinical investigation in disorders of bone and mineral metabolism at the American Society for Bone and Mineral Research…

Stay Connected

We comply with the HONcode standard for trustworthy health information: verify here.

Site provided by Vibrant Creative